

A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells

(ホメオボックスタンパク質 NKX6.1
による interleukin-6 の発現上昇を
介した Basal-like 乳癌細胞の
増殖制御機構)

リ ウンチョウ
李 文昭
Li Wenzhao

A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells

Wenzhao Li, Junji Itou*, Sunao Tanaka, Tomomi Nishimura, Fumiaki Sato, Masakazu Toi

Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

*Corresponding author:

Junji Itou

54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

Tel: +81-75-751-3660, Fax: +81-75-751-3616

e-mail: junji-itou@umin.ac.jp

Abstract

Among breast cancer subtypes, basal-like breast cancer is particularly aggressive, and research on the molecules involved in its pathology might contribute to therapy. In this study, we found that expression of NKX6.1, a homeobox transcription factor, is higher in basal-like breast cancer than in other subtypes. In loss-of-function experiments on basal-like breast cancer cell lines, NKX6.1-depleted cells exhibited reduced cell growth. Because cytokine interleukin-6 (IL-6) is expressed in basal-like breast cancer, and increases cell growth, we analyzed expression levels of *IL6*, an IL-6 gene, and observed reduced *IL6* expression in NKX6.1-depleted cells. In a reporter assay, *IL6* promoter activity was reduced by loss of NKX6.1 function. A pull-down assay showed that NKX6.1 binds to the proximal region in *IL6* promoter. These results indicate that NKX6.1 directly up-regulates *IL6* expression. To investigate further, we established cells with forced expression of IL-6. We observed that exogenous IL-6 expression restored the reduced cell growth of NKX6.1-depleted cells. Furthermore, orthotopic xenografts showed that NKX6.1-depleted cells lost the capacity for tumor formation. We therefore conclude that NKX6.1 is a factor for IL-6-regulated growth and tumor formation in basal-like breast cancer. Our findings facilitate profound understanding of basal-like breast cancer, and the development of suitable therapy.

Keywords:

Basal-like breast cancer / Cell growth / IL-6 / NKX6.1 / Transcription factor

1. Introduction

Breast cancer is the most common cancer in women [1]. It is classified into five subtypes, based on differences in gene expression patterns: luminal A; luminal B; human epidermal growth factor receptor 2 (HER2)-enriched; normal breast-like; and basal-like [2]. Among these, basal-like breast cancer is particularly aggressive, with the worst prognosis [3].

Basal-like breast cancer is characterized by the strong expression of basal markers such as cytokeratin 5/6 and 17 [2, 4, 5]. It is associated with up-regulation of mesenchymal markers, such as vimentin, smooth muscle actin, and N-cadherin, and reduced expression of epithelial markers, such as E-cadherin [6-8].

Transcription factors determine and maintain cellular characteristics through regulation of gene expression. Some transcription factors have been identified and analyzed with the aim of improving our understanding of the nature of basal-like breast cancer [9-12]. Although we now know about this cancer's molecular properties, we do not yet fully understand it, and the transcription factors responsible for basal-like breast cancer pathology still remains to be identified and investigated.

NKX homeobox protein is a family of transcription factors that possess a DNA binding domain [13], which amino acid sequence is conserved among family members. The NKX family of genes has been found to play a role in various types of cancer. For example, NKX2.1 functions as a proto-oncogene, and is closely associated with lung cancer [14-16]. NKX2.8 expresses in liver cancer, and regulates the expression of α -Fetoprotein, a fetal oncogene [17]. Loss of NKX3.1 function is an initiating event in prostate carcinogenesis [18]. NKX6.1 is a metastasis suppressor that regulates the epithelial-mesenchymal transition in cervical cancer [19]. With respect to breast cancer, some studies of the role of NKX family members in luminal breast cancer have been conducted [20, 21], but none have focused on the basal-like type. Given that NKX family members are involved in the pathologic functions of various cancers, it is reasonable to surmise that there might be as yet unrecognized NKX factor(s) active in basal-like breast cancer.

Interleukin-6 (IL-6) is a cytokine that plays a role in various biological activities, including cell growth and differentiation. In basal-like breast cancer, the level of IL-6 secretion is high, and the IL-6/Janus kinase (JAK) 2/signal transducer and activator of the transcription 3 (STAT3) pathway is active in regulating cell growth [22, 23]. In this

pathway, IL-6 binds to IL-6 receptor and activates JAK2 tyrosine kinase. Activated JAK2 proteins facilitate phosphorylation of STAT3. Phosphorylated-STAT3 (pSTAT3) is then translocated into the nucleus to regulate genes involved in apoptosis and proliferation. The IL-6/JAK2/STAT3 signaling pathway is therefore a potential target for cancer therapy [24-27].

Since *IL6*, an IL-6 gene, expression is involved in breast cancer cell growth, some studies have focused on the regulation of *IL6* expression in these cells. The epigenetic status of *IL6* expression differs between *IL6*-low luminal and *IL6*-high basal-like breast cancer cells [28]. The *IL6* promoter of basal-like breast cancer is demethylated, and this epigenetic activation is regulated by the IL-6 autocrine loop [29]. In luminal breast cancer, estrogen receptor, a nuclear receptor, inhibits *IL6* expression [30]. However, specific regulators for *IL6* expression in basal-like breast cancer have not been fully understood.

In this study we found that expression of NKX6.1, also known as NKX6A, is up-regulated in basal-like breast cancer, compared to other breast cancer subtypes. We show that NKX6.1 regulates *IL6* expression by binding to the *IL6* promoter to promote cell growth. In addition, NKX6.1 is involved in tumor formation. These results improve our understanding of basal-like breast cancer pathology, and might contribute to future therapy for this type of cancer.

2. Materials and methods

2.1 Cell culture and animal experiment

The breast cancer cell lines MCF10A, MCF-7, T-47D and MDA-MB-231 were obtained from American Type Culture Condition (Manassas, VA, USA). SUM159 cells were obtained from Asterand (Detroit, MI, USA). The colon cancer cell lines HCT116 and LoVo were obtained from RIKEN BioResource Center (Tsukuba, Japan).

MCF10A cells were maintained with DMEM/F12 containing 5% horse serum, 50 µg/mL EGF, 500 ng/mL hydrocortisone, 100 ng/mL cholera toxin and 10µg/mL insulin. MCF-7 cells were cultured with RPMI-1640 medium containing 1 nM estradiol and 10% fetal bovine serum (FBS). T-47D and MDA-MB-231 cells were cultured with RPMI-1640 containing 10% FBS. HCT116 cells were cultured with DMEM containing 10% FBS. SUM159 cells were maintained in Ham's F-12 nutrient mixture containing 5% FBS, 5 µg/mL insulin, 1 µg/mL hydrocortisone and 10 mM HEPES. LoVo cells

were maintained with Ham's F-12 nutrient mixture containing 10% FBS. In drug selection for infectants, 1 µg/mL puromycin or 10 µg/mL blasticidin S was used. For the xenograft assay, 1×10^6 cells were suspended in 40 µL of serum-free medium, mixed with equal amount of Matrigel (Corning, 356237, Bedford, MA, USA), and transplanted into the mammary fat pad of six-week-old NOD/SCID mice. In the same mouse, control and NKX6.1 knockdown cells were injected at the right and the left sides, respectively. The animal experiments in this study were approved by the Animal Research Committee of Kyoto University. All animals were maintained according to the Guide for the Care and Use of Laboratory Animals (National Institute of Health Publication).

2.2 Quantification of mRNA level

The primers used in this study are listed in Supplementary Table S1. For RNA-seq analysis and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis, RNA samples were extracted using TRIzol (Life Technologies, 15596026, Carlsbad, CA, USA) and PureLink RNA micro kits (Life Technologies, 12183-016). For RNA-seq analysis, total RNA samples from 3 independent extractions were pooled, and used for a cDNA library for analysis with HiSeq2500 system (Illumina, San Diego, CA, USA). Aligned data was normalized by RPKM method [31] and quantified with Strand NGS software (Strand Life Sciences, Aurora, CO, USA). For each qRT-PCR sample, 1 µg of total RNA was used for cDNA synthesis with SuperScript III (Life Technologies, 18080051). A 1:10 dilution of synthesized cDNA solution was used as the template in each qRT-PCR reaction with FastStart Universal SYBR Green Master (Roche, 04913850001, Mannheim, Germany). The StepOne Plus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) was used to run the qRT-PCR analyses. Amplification of *EF1A1* was used as an internal control. The following conditions were used: 95 °C for 10 min, then 40 cycles of 95 °C for 15 s, 60 °C for 30 s and 72 °C for 1 min. The relative mRNA levels and standard deviations were calculated according to the manufacturer's instructions. The cycle threshold value normalized by the *EF1A1* value was used for statistical analysis.

2.3 Immunoblotting

Rabbit anti-NKX6.1 antibody (1:500; Sigma, HPA036774, St. Louis, MO, USA), rabbit

anti-phospho-STAT3 Tyr705 (D3A7) antibody (1:1000; Cell Signaling technology, X9145, Danvers, MA, USA), rabbit anti-STAT3 (D3Z2G) antibody (1:1000; Cell Signaling Technology, 12640), rabbit anti-IL-6 antibody (1:1000; Cell Signaling Technology, 12153), rabbit anti-FLAG antibody (1:500; Sigma, F7425) and mouse anti-beta actin antibody (1:5000; Abcam, ab6276) were used for primary reactions. The Easy-Western-II detection system (Beacle, BCL-EZS21, Kyoto, Japan) was used instead of secondary antibody for rabbit IgG. We used goat anti-mouse IgG antibody conjugated to a peroxidase (1:50,000; Pierce biotechnology, 31340, Rochford, IL, USA) to detect beta-actin signals. Images were obtained with Ez-Capture II (ATTO, Tokyo, Japan) and ImageSaver5 Software (ATTO).

2.4 Construction of plasmid vectors

For NKX6.1 knockdown, we constructed an shRNA expression system. We used a lentiviral vector, pLKO.1 (Addgene, 8453), which has the human U6 promoter. The sequences of shRNAs are listed in Supplementary Table S2. To knockout the NKX6.1 gene, we used a lentiviral vector for the CRISPR/Cas9 system, lentiCRISPR v2 (Addgene, 52961). The target sequence for GFP control is 5'-CAACGTCTATATCATGGCCG-3', and that for NKX6.1 knockout is 5'-TGGGCCCGGTACCCCAAGCCG-3'.

To construct a FLAG-tagged gene, we inserted a synthesized double strand oligo, 5'-CACCATGGGCGGCGGCTCCGACTACAAGGACGACGACAAGTGA-3', into the cloning site of pENTR vector (Life Technologies, K2400-20, USA). The inserted sequence has an *NcoI* site, a GGGGS linker-FLAG coding sequence and an opal terminator. We cloned the *IL6* cDNA into the *NcoI* site using the In-Fusion HD cloning system (Takara Bio, Z9645N, Otsu, Japan). We then subcloned the FLAG or IL6-FLAG gene into the lentiviral vector, pLenti 6.3 (Life Technologies, V533-06).

To analyze *IL6* promoter activity, we cloned a fragment of the upstream region of the *IL6* transcription start site into the upstream region of the minimal promoter (miniP) of the pGL4.30 vector (Promega, Madison, WI, USA). The *IL6* promoter-miniP fragment was subcloned into the region between the *ClaI* - *SpeI* sites of the pLenti 6.3 vector. Mutations were introduced by In-Fusion system (Takara).

2.5 Growth assay

Cells were plated in 24-well plates at a density of 5×10^4 cells/well on day 0. On day 4, cells were trypsinized and resuspended in the medium as single cells. Four samples were collected from each well, and each sample was mixed with the same quantity of trypan blue solution. Viable cells were counted manually under a microscope. We calculated the mean of the four samples from each well as the cell number for that well, and analyzed four wells for each experimental group.

2.6 Immunostaining

For immunostaining, cells were cultured in chamber slides and fixed by 2% paraformaldehyde in PBS for 20 min at room temperature. For permeabilization, cells were treated with 0.1% Triton X-100 in PBS for 10 min. The primary antibodies we used were rabbit anti-NKX6.1 antibody (1:500; Sigma, HPA036774), rabbit anti-phospho-STAT3 Tyr705 (D3A7) antibody (1:100; Cell Signaling Technology, X9145), monoclonal anti-FLAG M2 antibody (1:1000; Sigma, F1804), and proliferating cell nuclear antigen (PCNA) (1:10; Dako, M0879 clone PC10, Glostrup, Denmark). The secondary antibody were goat anti-rabbit IgG antibody conjugated with Alexa Fluor 546 (1:1000; Life Technologies, A11010) and goat anti-mouse IgG antibody conjugated with Alexa 488 (1:1000; Life Technologies, A11001). Hoechst 33342 (1:1000; Dojindo, 346-07951, Kamimashiki, Japan) was used for counter staining.

TUNEL assay was performed using an In Situ Cell Death Detection Kit (Roche, 11684817910). Cells in chamber slides were fixed using 2% paraformaldehyde in PBS for 30 min at room temperature. After washing with PBS, fixed cells were permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate solution for 2 min on ice. Samples were then washed, and incubated with TUNEL reaction mixture for 2 h at 37°C. Goat anti-Fluorescein / Oregon Green antibody conjugated with Alexa Fluor 488 (1:1000; Life Technologies, A11096) was used to visualize the TUNEL signal, and Hoechst 33342 (1:1000) was used for counter staining. PCNA- and TUNEL-positive cells were counted manually in 1.5 mm² region in each staining.

2.7 Luciferase assay

To analyze the effect of NKX6.1 knockdown on *IL6* promoter, 2×10^4 cells containing *IL6* promoter reporter were seeded in a 96-well plate. Luciferase activity was measured on the second day after cell seeding using the Luciferase Reporter Assay System

(Promega, E2920). Luciferase activity was measured using the GloMax-Multi Detection System (Promega).

2.8 Pull-down assay

Cells were cultured in two 10 cm dishes and harvested at 70–80% confluence by adding 500 μ L binding buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM $MgCl_2$, 0.5% NP-40, 5% Glycerol) containing the protease inhibitor cocktail COMPLETE (Roche), and frozen at $-80^\circ C$. They were thawed at $37^\circ C$ for 10 min, then briefly sonicated. For the pull-down assay, we used Dynabeads MyOne Stretavidin T1 (Life Technologies, 65602) magnetic beads. The beads were blocked with 20 mg/mL BSA and 100 μ g/mL salmon sperm DNA. We mixed 1.2 mg of beads with 50 pmol of biotinylated oligos, and incubated the mixture for 10 min at room temperature. We then added 100 μ L of cell lysate and incubated the mixture for 30 min at $4^\circ C$ with or without competitor oligos. Samples were washed four times in 1 mL binding buffer, and the bound molecules were eluted with sample buffer.

2.9 Chromatin immunoprecipitation (ChIP) assay

ChIP assay was performed using a SimpleChIP Plus Enzymatic Chromatin IP Kit (Magnetic Beads) (Cell Signaling Technology, 9005), according to the manufacturer's protocol, with monoclonal anti-FLAG M2 antibody (10 μ L; Sigma, F7425). ChIP eluents were analyzed using quantitative PCR and regular PCR with primers targeting the proximal region in the *IL6* promoter (Table S1).

2.10 Electrophoretic mobility shift assay (EMSA)

EMSA was performed using 25 bp fragments of the *IL6* promoter having either the wide type or mutated sequence (Table S3). Fifteen microliters of SUM159 cell lysates, prepared as described above (section 2.8), were incubated with 50 pmol DNA fragments in a binding buffer (10mM Tris-HCl (pH7.5), 1 mM Na_2EDTA (pH8), 50 mM KCl, 5 mM $CaCl_2$, 3 mM $MgCl_2$, 5% glycerol and 0.05% Nonidet P-40) for 10 min at $37^\circ C$. After incubation, samples were electrophoresed with 6% polyacrylamide gel in $0.5 \times$ TBE buffer to separate the reaction batches. The gel was stained with ethidium bromide, and signal was detected with a Gel Doc EZ Imager (Bio-Rad laboratories, Hercules, CA, USA).

2.11 Statistical analysis

The qRT-PCR, cell growth, and luciferase assay results were analyzed using Student's *t*-test. Fisher's exact test was used to analyze differences in tumor formation ratios. Gene Expression Omnibus data was analyzed using Mann-Whitney *U* test. Statistical significance was inferred at $P < 0.05$. Error bars in all graphs indicate standard deviations.

3. Results

3.1 *NKX6.1* expression is up-regulated in basal-like breast cancer cells

NKX homeobox genes have been implicated in a wide variety of biological events, including cancer [14-21, 32]. To identify NKX factors for basal-like breast cancer, we performed expression screening of the NKX family of genes using qRT-PCR. We used the following human breast cancer cell lines: a non-tumorigenic cell line, MCF10A; two luminal cell lines, MCF-7 and T-47D; and two basal-like cell lines SUM159 and MDA-MB-231. We observed detectable amplification of six out of 14 NKX gene family members: *NKX1.2*, *NKX2.1*, *NKX2.8*, *NKX3.1*, and *NKX6.1* (Fig. 1A–E).

We express the mRNA levels for each gene as relative to the mean level in MCF-7 cells, which we define as 1. *NKX1.2* expression was higher in T-47D cells than in other cells (Fig. 1A). *NKX2.1* was not detected in MCF10A or SUM159 cells (Fig. 1B). In comparison with MCF-7 cells, *NKX2.8* expression was high in T-47D and MDA-MB-231 cells, and low in SUM159 cells (Fig. 1C). No remarkable difference of the *NKX3.1* level was observed (Fig. 1D). Unlike the other NKX family members, the *NKX6.1* expression was strongly up-regulated in basal-like breast cancer cell lines (Fig. 1E).

To analyze levels of NKX6.1 protein in breast cancer cell lines, we performed immunoblotting using anti-NKX6.1 antibody. We observed NKX6.1 signals in SUM159 and MDA-MB-231 cells, but not in MCF10A, MCF-7, or T-47D cells (Fig. 1F). We also performed immunostaining of NKX6.1 in these 5 cell lines and observed NKX6.1 signals in the nuclei of SUM159 and MDA-MB-231 cells, indicating that NK6.1 localizes in the nucleus, however, no signal was observed in the other 3 cell lines

(Fig. 1G-K). The results of immunoblotting and immunostaining suggest that NKX6.1 protein level is increased in basal-like breast cancer cell lines.

A dataset of basal-like breast cancer patients, GSE3744 [33], is available in the public gene expression database, Gene Expression Omnibus. In this dataset, 47 clinical samples (18 basal-like tumors and 29 others, including normal breast and non basal-like breast tumors) were included. RNA samples were extracted from tissue samples, and expression data were obtained using Affymetrix Human Genome U133 Plus 2.0 Arrays [33]. We used Mann-Whitney *U* test to analyze difference in *NKX6.1* level between basal-like and others. The result showed that *NKX6.1* expression is significantly higher in patients with basal-like breast cancer than in patients with normal breasts or other types of breast cancer (Fig. S1). *NKX6.1* expression is thus high in basal-like breast cancer both *in vitro* and *in vivo*.

3.2 *NKX6.1* contributes to the growth of basal-like breast cancer cells

To analyze the functions of NKX6.1, we constructed an shRNA expression system for NKX6.1. We used shGFP as a control. We introduced shRNA constructs into the basal-like breast cancer cell lines, SUM159 and MDA-MB-231. In both SUM159 and MDA-MB-231 cells, the *NKX6.1* mRNA level was significantly reduced in knockdown cells relative to the shGFP control group (Fig. 2A). Immunoblotting confirmed the reduction of NKX6.1 levels in knockdown cells (Fig. 2B). When we cultured NKX6.1 knockdown cells, reduced cell growth was observed. Therefore we analyzed cell growth by counting cell number. In the results, cell growth was significantly reduced in both the SUM159 and MDA-MB-231 cell lines (Fig. 2C,D).

Since an shRNA-mediated knockdown system has an off-target effect, it is necessary to validate the result via another loss-of-function system. We used a CRISPR/Cas9 system for this purpose [34, 35]. We established a CRISPR/Cas9-mediated NKX6.1 knockout cell line (crNKX6.1) in the MDA-MB-231 cells. CRISPR/Cas9 for *GFP* was constructed as a control (crGFP). We used immunoblotting to test whether NKX6.1 had been knocked out. Because the epitope region for the antibody used is upstream of our CRISPR target region, there was a truncated NKX6.1 signal in the crNKX6.1 cells (Fig. 2E). Because of an amino acid homology with the homeodomain of the NKX factors [36, 37], the truncated NKX6.1 lacked the homeodomain, implying that it was not able to bind to DNA, and to regulate

gene expression. To analyze its localization, we constructed cells with forced expression of intact NKX6.1-FLAG and truncated NKX6.1-FLAG, and conducted immunostaining with anti-FLAG antibody. We observed FLAG signals in the nuclei of SUM159 and MDA-MB-231 cells with forced expression of intact NKX6.1-FLAG. However, in cells with truncated NKX6.1-FLAG, FLAG signals were distributed to the cytoplasm, suggesting that truncated NKX6.1 has lower gene-regulation ability (Fig. S2).

In the cell proliferation assay, cell growth was significantly reduced in crNKX6.1 cells relative to their parental MDA-MB-231 and the crGFP cells (Fig. 2F). Thus both the shRNA-mediated knockdown and CRISPR/Cas9-mediated knockout systems displayed a reduction in cell growth, indicating that NKX6.1 promotes cell growth in basal-like breast cancer.

Next, we determined whether the reduction in cell number caused by NKX6.1 suppression was the result of cell cycle arrest, reduced cell survival, or both. To quantitatively analyze cell proliferation and cell death, we used PCNA staining and TUNEL assay, respectively (Fig. 2G,H, and S3). The percentage of PCNA-positive cells in the NKX6.1 loss-of-function group was significantly smaller than in the control group (Fig. 2G,H). In TUNEL assay, cells with NKX6.1 knockdown showed an increased percentage of TUNEL-positive cells, but no significant change was observed in NKX6.1 knockout cells (Fig. S3). This indicates that the reduced cell survival observed in NKX6.1 knockdown cells is an off-target effect. We therefore conclude that NKX6.1 promotes cell proliferation.

Since basal-like breast cancer features mesenchymal gene expression, and NKX6.1 acts as a regulator for epithelial and mesenchymal gene transcription in cervical cancer [19]. We analyzed changes in mRNA levels of an epithelial marker, *CDH1*, and mesenchymal markers, *VIM* and *CDH2*. *CDH1*, an E-cadherin gene, was not detected in either the SUM159 or the MDA-MB-231 cells. Expression of *VIM*, a vimentin gene, and *CDH2*, an N-cadherin gene, was not significantly affected by NKX6.1 knockdown or knockout (Fig. S4). This suggests that NKX6.1 is not involved in maintenance of mesenchymal status in basal-like breast cancer.

3.3 NKX6.1 up-regulates IL6 expression in basal-like breast cancer cells

Since NKX6.1 is a transcription factor, it must control the expression of a gene(s) involved in cell growth. To identify NKX6.1-regulated genes, RNA-seq analysis was

performed in SUM159 cells. We searched genes involving cell proliferation based on gene ontology, and obtained candidate genes (Supplementary Table S4). Among these candidates, this study focused on *IL6*, the gene encoding the IL-6 protein, because secretion of IL-6 is high in basal-like breast cancer, where it exhibits a paracrine effect to positively regulate cell growth [22, 23, 28]. We measured *IL6* mRNA levels in NKX6.1 knockdown and knockout cells by qRT-PCR. In both cell types, *IL6* expression was significantly reduced (Fig. 3A,B), indicating that NKX6.1 up-regulates *IL6* expression in basal-like breast cancer.

IL-6 is a signaling molecule that activates the JAK2/STAT3 pathway by binding to its receptors [24]. pSTAT3 is used as a marker for the activation of IL-6 signaling. In our control group, immunostaining with anti-pSTAT3 antibody showed that most cells were pSTAT3-positive, while both the SUM159 and MDA-MB-231 shNKX6.1 cells displayed a weak pSTAT3 signal (Fig. 3C–F). Immunoblotting showed that pSTAT3 levels were reduced following NKX6.1 knockdown, although the total quantity of STAT3 was not affected (Fig. 3G). This suggests that NKX6.1 supports IL-6 signaling through the up-regulation of *IL6* expression.

3.4 NKX6.1 activates *IL6* promoter

Next, we determined whether NKX6.1 directly stimulates *IL6* promoter activity utilizing a luciferase reporter system. We connected different lengths of upstream regions from the *IL6* transcription start site to a minimal promoter (Fig. S5A). We subcloned them into lentiviral vectors containing the firefly luciferase gene, and established *IL6* promoter reporter cell lines via lentiviral-mediated gene transfer. A construct containing a constitutive promoter, cytomegalovirus (CMV) immediate early promoter, was used as a control. To analyze whether NKX6.1 is involved in *IL6* promoter activity, we knocked-down NKX6.1 expression in these reporter cell lines and measured luciferase activity (Fig. S5B,C). Promoter activity was significantly reduced relative to the control in each construct, in all cells except those with a 20 bp fragment (Fig. 4A,B). This indicates that NKX6.1 up-regulates *IL6* expression by activating the *IL6* promoter.

In the cells containing a proximal 20 bp fragment, there was a small amount of promoter activity (Fig. S5B,C), which was not affected by NKX6.1 knockdown (Fig. 4A,B). This indicates that NKX6.1 does not activate this 20 bp region. The activity of

cells with the 20 bp fragment was less even than the reduced activity of the NKX6.1 knockdown cells with the longer fragments, suggesting that the 20 bp region lacks the sequences necessary to respond to some transcription factors, including NKX6.1.

A transcription factor binds to DNA to regulate gene expression. To analyze the binding potential of NKX6.1 to the *IL6* promoter region, we performed a pull-down assay using 100 bp fragments from the region upstream of the *IL6* transcription start site. NKX6.1 did bind to this 100 bp fragment (Fig. 4C). In competitor assays using the proximal 100 bp, 50 bp, and 20 bp fragments, NKX6.1 binding was blocked by the 100 bp and 50 bp fragments but not by the 20 bp fragment (Fig. 4D). We can therefore conclude that NKX6.1 binds to the promoter region of the *IL6* gene and activates *IL6* expression.

To confirm that NKX6.1 binds to the *IL6* promoter region in living cells, we performed ChIP assay. We established SUM159 cells with forced expression of NKX6.1-FLAG. FLAG-expressing cells were used as a control. Anti-FLAG antibody was used for precipitation. In the results of PCR analyses of the *IL6* promoter region in precipitated samples, we observed enrichment of the region in NKX6.1-FLAG samples (Fig. 4E, F). The results indicate that NKX6.1 directly binds to the *IL6* promoter region in living cancer cells.

Previous study has reported that NKX6.1 binds to A/T-rich sequence flanked by G/C residues [38]. We found two candidate sequences, site1 and site2, in the region between 50 bp and 20 bp (Fig. 4G). To identify NKX6.1-response site, we mutated the sequence of each candidate site in the reporter having 50 bp fragment (Mut1 and Mut2 shown in Fig. 4G). We knocked-down NKX6.1 expression in SUM159 cells having the mutant reporter. We observed low luciferase activity and loss of knockdown effect in the cells having Mut1 construct (Fig. 4H, S5D), suggesting that site1 is the response site for NKX6.1. In Mut2 construct, luciferase activity was significantly reduced in NKX6.1 knockdown (Fig. 4H). This result indicates that NKX6.1 does not work on this site.

To verify that NKX6.1 binds to the sequence of site1, we carried out EMSA and DNA pull-down assay. We used the wild type and mutated DNA fragments shown in Table S3. In EMSA, we detected a shifted band in wild type fragments, while no band was observed at the same position in the mutated fragments (Fig. S5E, arrow), indicating that a DNA-protein complex is formed at that sequence. To determine whether NKX6.1 participates in this DNA-protein complex, we performed pull-down

assay and detected NKX6.1 binding. We observed NKX6.1 binding in wild type fragments, but not in the mutated fragments (Fig. S5F). This is consistent with the results of promoter assay and EMSA, and strongly suggests that NKX6.1 binds to the sequence to up-regulate *IL6* expression.

3.5 The NKX6.1 - IL-6 network regulates cell growth

In basal-like breast cancer cell lines, loss of NKX6.1 function reduces *IL6* expression and cell growth. We performed rescue experiments to investigate whether the reduced cell growth is caused by the reduction in *IL6* expression. We established cells with forced expression of IL-6-FLAG, and used FLAG expression as a control. The increase in levels of IL-6 in the IL-6-FLAG expressing cells was confirmed by immunoblotting on supernatant (Fig. 5A, B). The reduction in pSTAT3 levels that occurred as a result of loss of NKX6.1 function was reversed in the IL-6-FLAG expressing cells (Fig. 5C,D).

There was no significant difference between the growth of cells with forced FLAG- and IL-6-FLAG expression in shGFP or crGFP cells, which featured normal NKX6.1 expression (Fig. 5E,F). This suggests that these cells have a maximum level of growth activity and that additional IL-6 was not able to enhance their growth beyond this. Cell number was reduced in the FLAG-expressing cells as a result of loss of NKX6.1 function. This reduction was recovered by exogenous IL-6 expression. This indicates that the NKX6.1 - IL-6 network up-regulates cell growth in basal-like breast cancer cell lines.

Next, we used PCNA staining to determine whether the cell growth recovery by exogenous IL-6 expression is caused by a restoration of cell proliferation ability (Fig. S6). In shGFP or crGFP cells, there was no significant difference in the PCNA-positive percentage between cells with FLAG- or IL-6-FLAG expression. In NKX6.1-depleted cells, reduced cell proliferation was observed, and this reduction was recovered by exogenous IL-6 expression (Fig. S6). This supports the notion that NKX6.1 promotes cell proliferation through IL-6 up-regulation.

3.6 NKX6.1 is required for tumor formation

To investigate the regulation of cell growth by the NKX6.1 - IL-6 network *in vivo*, we performed xenograft experiments with SUM159 cells. Cells were transplanted into the fat-pad of six-week-old female NOD/SCID mice. We analyzed tumor formation four

weeks after transplantation. In the FLAG-expressing control group, shGFP cells showed tumors at all the points where they had been transplanted (Fig. 6A). However, there was a drastic reduction in the tumor formation rate in shNKX6.1 cells, indicating that NKX6.1 is required for tumor formation. Because most of the shNKX6.1 cell transplants showed no tumor formation, we were not able to compare size difference of tumor size between the tumors of shGFP control and shNKX6.1 cells.

We next assessed the extent of restoration of this reduced tumor formation rate as a result of IL-6 forced expression. However, the reduced tumor formation capacity of the shNKX6.1 cells was not restored by IL-6-FLAG expression (Fig. 6A–C). This indicates that IL-6 expression alone is insufficient to restore the loss of NKX6.1 function in tumor formation.

3.7 A negative feedback loop in the NKX6.1 - IL-6 network

Our results showed that NKX6.1 controls tumor formation and cell growth. The NKX6.1 - IL-6 network plays a role in NKX6.1-regulated cell growth. Some molecular events are known to have positive or negative feedback loops. If there is such a feedback loop in the NKX6.1 - IL-6 network, *IL6* expression might either promote or suppress *NKX6.1* expression. To address this, we analyzed whether *NKX6.1* expression is affected by IL-6 knockdown, using the previously established shRNA-mediated IL-6 knockdown system [22, 23]. The qRT-PCR analysis showed that *NKX6.1* expression was increased as a result of IL-6 knockdown (Fig. 7A). Since IL-6 signaling activates the JAK2/STAT3 pathway and pSTAT3 regulates gene expression [24], we established an shRNA-mediated STAT3 knockdown system, and examined whether the *NKX6.1* level was increased by STAT3 knockdown. *NKX6.1* expression was significantly up-regulated by STAT3 knockdown (Fig. 7B). These indicate that there is a negative feedback loop in the NKX6.1 - IL-6 network (Fig. 7C).

To investigate whether NKX6.1 regulates *IL6* expression in other types of cancer, we used two colon cancer cell lines, HCT116 and LoVo, and analyzed *IL6* mRNA levels in shGFP and shNKX6.1 groups. In the HCT116 cells, there was no detectable *IL6* expression. *IL6* was expressed in the LoVo cells, but the mRNA level was not affected by NKX6.1 knockdown (Fig. S7). This indicates that NKX6.1 does not regulate IL-6 expression in colon cancer.

3.8 Clinical significance of *NKX6.1* in breast cancer

We analyzed the relationship between *NKX6.1* expression and prognosis using the SurvExpress platform [39]. Cohort studies on invasive breast cancer have shown that high *NKX6.1* expression is associated with poor clinical outcome (Fig. S8) [40, 41]. This finding suggests that *NKX6.1* would affect survival outcome of breast cancer.

4. Discussion

Since the molecular properties of different types of cancer vary, studies that characterize a particular type contribute towards both understanding of that type and the establishment of a specific targeted therapy for it. In this study, we observed up-regulation of *NKX6.1* expression in basal-like breast cancer and direct regulation of *IL6* expression by *NKX6.1*. This *NKX6.1* - *IL-6* network promotes cell growth in basal-like breast cancer cells. We also found that *NKX6.1* is required for tumor formation in xenografted cells. This indicates that *NKX6.1* is one of the factors for malignancy in basal-like breast cancer.

NKX factors are known to be developmental transcription factors. In the embryonic stages, *NKX6.1* expression has been reported in the central nervous system [42-44], gut [44], and pancreas [45]. *NKX6.1* is also expressed in the adult pancreas [46]. In the developing nervous system, it acts as a factor for ventral neural patterning during generation of motor and V2 neurons [38, 47]. Loss of *NKX6.1* function affects astrocyte migration and differentiation, and reduces expression of a fibrous astrocyte marker and a regulator for white matter astrocyte development [48]. In the pancreas, *NKX6.1* maintains the population of beta cells [46, 49]. A study based on conditional forced expression and a knockout system showed that *NKX6.1* is required for beta cell differentiation from endocrine precursor cells [50]. Conditional knockout of *NKX6.1* in mature beta cells results in conversion to delta cells, which indicates that it functions to maintain the beta cell character [50]. In pancreatic beta cells, *NKX6.1* regulates expression of genes for insulin production and secretion [51], glucose uptake [51], and cell proliferation [52]. It also positively regulates *NKX6.1* gene expression in pancreatic beta cells, but not in fibroblasts [38]. The different roles of *NKX6.1* among neurons, glial cells and pancreatic beta cells suggest that its function is modified in a cell-type-dependent manner.

A recent study has shown that NKX6.1 suppresses cervical cancer metastasis [19]. In cervical cancer cell lines, ectopic NKX6.1 represses expression of the mesenchymal marker gene *VIM* by recruiting a chromatin-remodeling factor, BAF155. At the same time, NKX6.1 recruits another chromatin-remodeling factor, RBBP7, to activate expression of the *CDH1* gene that encodes a cell-cell adhesion molecule. We analyzed the function of NKX6.1 in basal-like breast cancer that expresses mesenchymal marker genes. We found that NKX6.1 expression was high in basal-like breast cancer, and loss of NKX6.1 function did not significantly affect expression of epithelial or mesenchymal marker genes. This suggests that NKX6.1 is not involved in preservation of the mesenchymal character in basal-like breast cancer. Given that the function of NKX6.1 varies among cell types in normal cells, functional divergence in cancer cells is likely to be the result of differences between cancer types. In support of this hypothesis, the NKX6.1 - IL-6 network exists in basal-like breast cancer but not in colon cancer. This study has therefore revealed the function of NKX6.1 in basal-like breast cancer only.

IL-6 is a signaling protein that is involved in cell growth in breast cancer, and is strongly expressed in basal-like breast cancer [22, 28]. This study revealed a part of the regulatory mechanism of *IL6* expression in basal-like breast cancer cells. Previously, several studies have investigated the regulators of *IL6* expression in various cell types. In T cells, RELA/p65 activates *IL6* promoter [53]. *IL6* expression is activated by RELA/p65 introduction and by RELA/p65 and C/EBP co-introduction in luminal breast cancer and osteosarcoma, respectively, and this is impaired by administration of 17beta-estradiol [54]. A study based on renal mesangial cells revealed that *IL6* expression is regulated by the transcription factors AP-1, CREB, C/EBP and RELA/p65 [55]. A small GTPase Rac1 activates RELA/p65, which results in up-regulation of *IL6* expression and activation of IL-6 signaling [56]. In B cells, C/EBP, AP-1 and RELA/p65 are involved in *IL6* expression [57]. In HeLa cells, *IL6* promoter activity was stimulated by a dominant negative c-Jun transcription factor, as well as by C/EBP and RELA/p65 [58]. Notch signaling serves as an activator for *IL6* expression in macrophages [59]. In this study, we discovered that NKX6.1 up-regulates *IL6* expression in basal-like breast cancer. We identified the response region to NKX6.1 in *IL6* promoter. Our pull-down assay showed that NKX6.1 possesses a binding potential to the identified region of *IL6* promoter implying that NKX6.1 directly regulates *IL6*

expression. These findings characterize NKX6.1 as an *IL6* regulator, which might provide novel insights into *IL6* regulation in basal-like breast cancer cells.

Basal-like breast cancer is heterogenous, and we previously reported that *IL6* expressing cells promotes growth of *IL6* negative cells [23]. That suggests that if a small population of cells acquires NKX6.1 expression in a cancer tissue, these cells activate cell growth of surrounding cancer cells via IL-6 expression. Therefore, prevention of NKX6.1 function might be one of therapeutic strategies for basal-like breast cancer.

Publicly available clinical data for invasive breast cancer have shown that NKX6.1-high patients have poor clinical outcome. If a therapy targeting NKX6.1 function is established, it will be used to care such patients. However, loss of NKX6.1 function affects pancreatic beta cell function and maintenance, and causes cervical cancer metastasis. Therefore, approaches for avoidance of undesirable effects, such as drug delivery system to breast cancer, would be required in NKX6.1-targeted therapy.

In this study, we analyzed the NKX6.1 function in basal-like breast cancer. NKX6.1 binds to the *IL6* promoter region and up-regulates the *IL6* expression, which results in the promotion of IL-6 signaling and cell growth. In addition, the results of our knockdown experiment for IL-6 expression imply that IL-6 signaling down-regulates NKX6.1 expression. This negative feedback loop could function to tune the NKX6.1 expression level and the activity of the downstream factors of NKX6.1. Furthermore, we observed the loss of tumor formation ability in NKX6.1-depleted cells. The mechanisms for mammary tumorigenesis regulation are complex, involving both tumor-intrinsic and -extrinsic factors. The activation of proto-oncogenes and oncogenic signaling pathways are crucial intrinsic factors in tumor formation and progression. In the tumor microenvironment, tumor cells develop tumor stroma, endothelial cells, cancer-associated fibroblasts, and bone marrow-derived cells, which are considered the principle determinants of tumor progression. These factors work together to regulate tumor formation and progression. Although *in vitro* studies have shown that IL-6 signaling promotes basal-like breast cancer cell growth and expands tumor-initiating breast cancer cells [22, 23], the role of IL-6 in mammary tumorigenesis is still unclear. Here, we observed the loss of tumor formation ability in NKX6.1-depleted cells. Exogenous IL-6 expression proved unable to recover this ability, although it restored the reduced cell growth of NKX6.1-depleted cells. This suggests that the

NKX6.1-regulated tumor formation ability requires the orchestrated interaction of several factors, and that IL-6 signaling alone is insufficient for tumor formation. It also points to a microenvironment-dependent role of the NKX6.1 - IL-6 network for mammary tumorigenesis.

5. Conclusions

Embryonic and cancer cells share several cellular properties, such as proliferation, motility and stemness. During embryonic development, accurate regulation of transcription factors is required for cells to differentiate into proper states, and inappropriate expression of transcription factors could lead to failure in differentiation or loss of cell identity and function. In cancer cells, up-regulation of embryonic transcription factors alters gene expression, which promotes tumor cell growth, survival and motility, as well as changes in cell state, such as epithelial-mesenchymal transitions. In this study, we found that the NKX6.1 homeobox transcription factor is up-regulated in basal-like breast cancer. Furthermore, we showed that NKX6.1 directly regulates *IL6* expression and promotes cell growth via the NKX6.1 - IL-6 network. This study improves our understanding of basal-like breast cancer and contributes to the development of therapeutic methods for basal-like breast cancer in future.

Acknowledgements

We thank the members of departments of breast surgery, and of hepato-biliary-pancreatic surgery and transplantation for sharing laboratory equipment. We thank the Medical Research Support Center, Graduate School of Medicine, Kyoto University for technical assistance. RNA-seq was performed by Eurofins Genomics Japan. Financial support was provided by Taiho Pharmaceutical Co., Ltd.

Conflict of interest

Wenzhao Li, Sunao Tanaka, Tomomi Nishimura and Fumiaki Sato declare no competing interests. Junji Ito is an employee of Kyoto University's Sponsored Research Program funded by Taiho Pharmaceutical Co., Ltd. Masakazu Toi received research funding from Taiho Pharmaceutical Co., Ltd. The funding sources had no role in the study design, experiment, analysis, interpretation or writing the manuscript. The corresponding author had full access to the data and final responsibility for submission.

References

- [1] J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, F. Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, *Int J Cancer* 136 (2015) E359-386.
- [2] T. Sørlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, T. Thorsen, H. Quist, J.C. Matese, P.O. Brown, D. Botstein, P.E. Lønning, A.L. Børresen-Dale, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, *Proc Natl Acad Sci U S A* 98 (2001) 10869-10874.
- [3] J. Leidy, A. Khan, D. Kandil, Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features, *Arch Pathol Lab Med* 138 (2014) 37-43.
- [4] C.M. Perou, T. Sørlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lønning, A.L. Børresen-Dale, P.O. Brown, D. Botstein, Molecular portraits of human breast tumours, *Nature* 406 (2000) 747-752.
- [5] E. Charafe-Jauffret, C. Ginestier, F. Monville, P. Finetti, J. Adelaide, N. Cervera, S. Fekairi, L. Xerri, J. Jacquemier, D. Birnbaum, F. Bertucci, Gene expression profiling of breast cell lines identifies potential new basal markers, *Oncogene* 25 (2006) 2273-2284.
- [6] T. Blick, E. Widodo, H. Hugo, M. Waltham, M.E. Lenburg, R.M. Neve, E.W. Thompson, Epithelial mesenchymal transition traits in human breast cancer cell lines, *Clin Exp Metastasis* 25 (2008) 629-642.
- [7] H. Jeong, Y.J. Ryu, J. An, Y. Lee, A. Kim, Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype, *Histopathology* 60 (2012) E87-95.
- [8] D. Sarrio, S.M. Rodriguez-Pinilla, D. Hardisson, A. Cano, G. Moreno-Bueno, J. Palacios, Epithelial-mesenchymal transition in breast

- cancer relates to the basal-like phenotype, *Cancer Res* 68 (2008) 989-997.
- [9] M.E. Rieger, A.H. Sims, E.R. Coats, R.B. Clarke, K.J. Briegel, The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers, *Mol Cell Biol* 30 (2010) 4267-4279.
 - [10] W.T. Khaled, S. Choon Lee, J. Stingl, X. Chen, H. Raza Ali, O.M. Rueda, F. Hadi, J. Wang, Y. Yu, S.F. Chin, M. Stratton, A. Futreal, N.A. Jenkins, S. Aparicio, N.G. Copeland, C.J. Watson, C. Caldas, P. Liu, BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells, *Nat Commun* 6 (2015) 5987.
 - [11] Q.S. Wang, P.Z. Kong, X.Q. Li, F. Yang, Y.M. Feng, FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer, *Breast Cancer Res* 17 (2015) 30.
 - [12] Y. Su, A. Subedee, N. Bloushtain-Qimron, V. Savova, M. Krzystanek, L. Li, A. Marusyk, D.P. Tabassum, A. Zak, M.J. Flacker, M. Li, J.J. Lin, S. Sukumar, H. Suzuki, H. Long, Z. Szallasi, A. Gimelbrant, R. Maruyama, K. Polyak, Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer, *Cell Rep* 11 (2015) 1549-1563.
 - [13] Y. Kim, M. Nirenberg, Drosophila NK-homeobox genes, *Proc Natl Acad Sci U S A* 86 (1989) 7716-7720.
 - [14] L. Yang, M. Lin, W.J. Ruan, L.L. Dong, E.G. Chen, X.H. Wu, K.J. Ying, Nkx2-1: a novel tumor biomarker of lung cancer, *J Zhejiang Univ Sci B* 13 (2012) 855-866.
 - [15] J.B. Tagne, S. Gupta, A.C. Gower, S.S. Shen, S. Varma, M. Lakshminarayanan, Y. Cao, A. Spira, T.L. Volkert, M.I. Ramirez, Genome-wide analyses of Nkx2-1 binding to transcriptional target genes uncover novel regulatory patterns conserved in lung development and tumors, *PLoS One* 7 (2012) e29907.
 - [16] C.M. Li, V. Gocheva, M.J. Oudin, A. Bhutkar, S.Y. Wang, S.R. Date, S.R. Ng, C.A. Whittaker, R.T. Bronson, E.L. Snyder, F.B. Gertler, T. Jacks, Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis, *Genes Dev* 29 (2015) 1850-1862.

- [17] Y. Kajiyama, J. Tian, J. Locker, Regulation of alpha-fetoprotein expression by Nkx2.8, *Mol Cell Biol* 22 (2002) 6122-6130.
- [18] M.M. Shen, C. Abate-Shen, Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis, *Dev Dyn* 228 (2003) 767-778.
- [19] H.J. Li, P.N. Yu, K.Y. Huang, H.Y. Su, T.H. Hsiao, C.P. Chang, M.H. Yu, Y.W. Lin, NKX6.1 functions as a metastatic suppressor through epigenetic regulation of the epithelial-mesenchymal transition, *Oncogene* (2015).
- [20] M. Dentice, C. Luongo, A. Elefante, R. Romino, R. Ambrosio, M. Vitale, G. Rossi, G. Fenzi, D. Salvatore, Transcription factor Nkx-2.5 induces sodium/iodide symporter gene expression and participates in retinoic acid- and lactation-induced transcription in mammary cells, *Mol Cell Biol* 24 (2004) 7863-7877.
- [21] K.A. Holmes, J.S. Song, X.S. Liu, M. Brown, J.S. Carroll, Nkx3-1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity, *Cancer Res* 68 (2008) 7380-7385.
- [22] L.L. Marotta, V. Almendro, A. Marusyk, M. Shipitsin, J. Schemme, S.R. Walker, N. Bloushtain-Qimron, J.J. Kim, S.A. Choudhury, R. Maruyama, Z. Wu, M. Gonen, L.A. Mulvey, M.O. Bessarabova, S.J. Huh, S.J. Silver, S.Y. Kim, S.Y. Park, H.E. Lee, K.S. Anderson, A.L. Richardson, T. Nikolskaya, Y. Nikolsky, X.S. Liu, D.E. Root, W.C. Hahn, D.A. Frank, K. Polyak, The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors, *J Clin Invest* 121 (2011) 2723-2735.
- [23] J. Itou, S. Tanaka, F. Sato, R. Akiyama, Y. Kawakami, M. Toi, An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer, *Biochimica et biophysica acta* 1853 (2015) 27-40.
- [24] Y. Guo, F. Xu, T. Lu, Z. Duan, Z. Zhang, Interleukin-6 signaling pathway in targeted therapy for cancer, *Cancer treatment reviews* 38 (2012) 904-910.

- [25] P.C. Heinrich, I. Behrmann, G. Müller-Newen, F. Schaper, L. Graeve, Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway, *Biochem J* 334 (Pt 2) (1998) 297-314.
- [26] K. Imada, W.J. Leonard, The Jak-STAT pathway, *Mol Immunol* 37 (2000) 1-11.
- [27] R. Rodriguez-Barrueco, J. Yu, L.P. Saucedo-Cuevas, M. Olivan, D. Llobet-Navas, P. Putcha, V. Castro, E.M. Murga-Penas, A. Collazo-Lorduy, M. Castillo-Martin, M. Alvarez, C. Cordon-Cardo, K. Kalinsky, M. Maurer, A. Califano, J.M. Silva, Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers, *Genes Dev* 29 (2015) 1631-1648.
- [28] M.N. Ndlovu, C. Van Lint, K. Van Wesemael, P. Callebert, D. Chalbos, G. Haegeman, W. Vanden Berghe, Hyperactivated NF- κ B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells, *Mol Cell Biol* 29 (2009) 5488-5504.
- [29] L. D'Anello, P. Sansone, G. Storci, V. Mitrugno, G. D'Uva, P. Chieco, M. Bonafe, Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells, *Mol Cancer* 9 (2010) 300.
- [30] R. Galien, T. Garcia, Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site, *Nucleic Acids Res* 25 (1997) 2424-2429.
- [31] A. Mortazavi, B.A. Williams, K. McCue, L. Schaeffer, B. Wold, Mapping and quantifying mammalian transcriptomes by RNA-Seq, *Nat Methods* 5 (2008) 621-628.
- [32] P.W. Holland, Evolution of homeobox genes, *Wiley Interdiscip Rev Dev Biol* 2 (2013) 31-45.
- [33] A.L. Richardson, Z.C. Wang, A. De Nicolo, X. Lu, M. Brown, A. Miron, X. Liao, J.D. Iglehart, D.M. Livingston, S. Ganesan, X chromosomal abnormalities in basal-like human breast cancer, *Cancer Cell* 9 (2006) 121-132.

- [34] S.W. Cho, S. Kim, J.M. Kim, J.S. Kim, Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease, *Nat Biotechnol* 31 (2013) 230-232.
- [35] N.E. Sanjana, O. Shalem, F. Zhang, Improved vectors and genome-wide libraries for CRISPR screening, *Nat Methods* 11 (2014) 783-784.
- [36] H. Inoue, A. Rudnick, M.S. German, R. Veile, H. Donis-Keller, M.A. Permutt, Isolation, characterization, and chromosomal mapping of the human *Nkx6.1* gene (*NKX6A*), a new pancreatic islet homeobox gene, *Genomics* 40 (1997) 367-370.
- [37] R.G. Mirmira, H. Watada, M.S. German, Beta-cell differentiation factor *Nkx6.1* contains distinct DNA binding interference and transcriptional repression domains, *J Biol Chem* 275 (2000) 14743-14751.
- [38] T. Iype, D.G. Taylor, S.M. Ziesmann, J.C. Garmey, H. Watada, R.G. Mirmira, The transcriptional repressor *Nkx6.1* also functions as a deoxyribonucleic acid context-dependent transcriptional activator during pancreatic beta-cell differentiation: evidence for feedback activation of the *nkx6.1* gene by *Nkx6.1*, *Mol Endocrinol* 18 (2004) 1363-1375.
- [39] R. Aguirre-Gamboa, H. Gomez-Rueda, E. Martinez-Ledesma, A. Martinez-Torteya, R. Chacolla-Huaringa, A. Rodriguez-Barrientos, J.G. Tamez-Pena, V. Trevino, SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis, *PLoS One* 8 (2013) e74250.
- [40] D.Y. Wang, S.J. Done, D.R. Mc Cready, W.L. Leong, Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations, *Breast Cancer Res* 16 (2014) R71.
- [41] L.J. van 't Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M. Mao, H.L. Peterse, K. van der Kooy, M.J. Marton, A.T. Witteveen, G.J. Schreiber, R.M. Kerkhoven, C. Roberts, P.S. Linsley, R. Bernards, S.H. Friend, Gene expression profiling predicts clinical outcome of breast cancer, *Nature* 415 (2002) 530-536.
- [42] M. Qiu, K. Shimamura, L. Sussel, S. Chen, J.L. Rubenstein, Control of anteroposterior and dorsoventral domains of *Nkx-6.1* gene expression

- relative to other Nkx genes during vertebrate CNS development, *Mech Dev* 72 (1998) 77-88.
- [43] M. Sander, S. Paydar, J. Ericson, J. Briscoe, E. Berber, M. German, T.M. Jessell, J.L. Rubenstein, Ventral neural patterning by Nkx homeobox genes: Nkx6.1 controls somatic motor neuron and ventral interneuron fates, *Genes Dev* 14 (2000) 2134-2139.
 - [44] S.B. Nelson, C. Janiesch, M. Sander, Expression of Nkx6 genes in the hindbrain and gut of the developing mouse, *J Histochem Cytochem* 53 (2005) 787-790.
 - [45] A. Rudnick, T.Y. Ling, H. Odagiri, W.J. Rutter, M.S. German, Pancreatic beta cells express a diverse set of homeobox genes, *Proc Natl Acad Sci U S A* 91 (1994) 12203-12207.
 - [46] B.L. Taylor, J. Benthuisen, M. Sander, Postnatal beta-cell proliferation and mass expansion is dependent on the transcription factor Nkx6.1, *Diabetes* 64 (2015) 897-903.
 - [47] J. Briscoe, A. Pierani, T.M. Jessell, J. Ericson, A homeodomain protein code specifies progenitor cell identity and neuronal fate in the ventral neural tube, *Cell* 101 (2000) 435-445.
 - [48] X. Zhao, Y. Chen, Q. Zhu, H. Huang, P. Teng, K. Zheng, X. Hu, B. Xie, Z. Zhang, M. Sander, M. Qiu, Control of astrocyte progenitor specification, migration and maturation by Nkx6.1 homeodomain transcription factor, *PLoS One* 9 (2014) e109171.
 - [49] M. Sander, L. Sussel, J. Connors, D. Scheel, J. Kalamaras, F. Dela Cruz, V. Schwitzgebel, A. Hayes-Jordan, M. German, Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of beta-cell formation in the pancreas, *Development* 127 (2000) 5533-5540.
 - [50] A.E. Schaffer, B.L. Taylor, J.R. Benthuisen, J. Liu, F. Thorel, W. Yuan, Y. Jiao, K.H. Kaestner, P.L. Herrera, M.A. Magnuson, C.L. May, M. Sander, Nkx6.1 controls a gene regulatory network required for establishing and maintaining pancreatic Beta cell identity, *PLoS Genet* 9 (2013) e1003274.
 - [51] B.L. Taylor, F.F. Liu, M. Sander, Nkx6.1 is essential for maintaining the functional state of pancreatic beta cells, *Cell Rep* 4 (2013) 1262-1275.

- [52] J.S. Tessem, L.G. Moss, L.C. Chao, M. Arlotto, D. Lu, M.V. Jensen, S.B. Stephens, P. Tontonoz, H.E. Hohmeier, C.B. Newgard, Nkx6.1 regulates islet beta-cell proliferation via Nr4a1 and Nr4a3 nuclear receptors, *Proc Natl Acad Sci U S A* 111 (2014) 5242-5247.
- [53] N. Mori, F. Shirakawa, H. Shimizu, S. Murakami, S. Oda, K. Yamamoto, S. Eto, Transcriptional regulation of the human interleukin-6 gene promoter in human T-cell leukemia virus type I-infected T-cell lines: evidence for the involvement of NF-kappa B, *Blood* 84 (1994) 2904-2911.
- [54] B. Stein, M.X. Yang, Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta, *Mol Cell Biol* 15 (1995) 4971-4979.
- [55] C. Grassl, B. Luckow, D. Schlondorff, U. Dendorfer, Transcriptional regulation of the interleukin-6 gene in mesangial cells, *J Am Soc Nephrol* 10 (1999) 1466-1477.
- [56] T.R. Faruqi, D. Gomez, X.R. Bustelo, D. Bar-Sagi, N.C. Reich, Rac1 mediates STAT3 activation by autocrine IL-6, *Proc Natl Acad Sci U S A* 98 (2001) 9014-9019.
- [57] M. Baccam, S.Y. Woo, C. Vinson, G.A. Bishop, CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-kappa B, AP-1, and C/EBP, *J Immunol* 170 (2003) 3099-3108.
- [58] L. Faggioli, C. Costanzo, M. Donadelli, M. Palmieri, Activation of the Interleukin-6 promoter by a dominant negative mutant of c-Jun, *Biochim Biophys Acta* 1692 (2004) 17-24.
- [59] W. Wongchana, T. Palaga, Direct regulation of interleukin-6 expression by Notch signaling in macrophages, *Cell Mol Immunol* 9 (2012) 155-162.

Figure legends

Fig. 1. Expression of NKX factors in breast cancer cell lines. (A-E) Quantification of expression levels of *NKX1.2* (A), *NKX2.1* (B), *NKX2.8* (C), *NKX3.1* (D), and *NKX6.1* (E) in breast cancer cell lines. Value of MCF-7 cells was set as 1. Gray bars represent basal-like breast cancer cell lines. (F) Immunoblotting shows that NKX6.1 signals were detected in basal-like breast cancer cell lines SUM159 and MDA-MB-231, but not detected in MCF10A, MCF-7 and T-47D cells. Anti-beta actin antibody was used as an internal control. (G-K) Immunostaining were performed to detect NKX6.1 expression in MCF10A (G), MCF-7 (H), T-47D (I), SUM159 (J), and MDA-MB-231 (K). Nuclei were visualized by Hoechst 33342 (G'-K'). n.d.: not detected. Student's *t*-test was used to analyze significance. *: $P < 0.05$, **: $P < 0.01$. Error bars represent the standard deviation. Scale bars indicate 100 μm .

Fig. 2. Loss of NKX6.1 function affects cell growth in basal-like breast cancer cells.

(A) Treatment with shRNA for *NKX6.1* reduced the *NKX6.1* mRNA level in SUM159 and MDA-MB-231 cells. (B) Immunoblotting showed reduction in NKX6.1 protein level in knockdown cells. (C,D) Cell growth was reduced in cells expressing shNKX6.1 in both SUM159 (C) and MDA-MB-231 cells (D). Cell number was counted manually at day 4. (E) Immunoblotting revealed the effect of CRISPR/Cas9-mediated NKX6.1 knockout: a truncated NKX6.1 signal was apparent in crNKX6.1 cells. (F) Cell growth was reduced in NKX6.1-knockout MDA-MB-231 cells. Cell number was counted manually at day 4. (G, H) Ratio of PCNA-positive cells in NKX6.1 knockdown (G) and knockout cells (H). Student's *t*-test was used to analyze significance. *: $P < 0.05$, **: $P < 0.01$. Error bars represent the standard deviations.

Fig. 3. NKX6.1 positively regulates *IL6* expression.

(A,B) Relative *IL6* mRNA level following NKX6.1 knockdown (A) and knockout cells (B) was analyzed by qRT-PCR. (C-F) Immunostaining analysis of levels of pSTAT3, a marker of IL-6 signaling, in SUM159 and MDA-MB-231 cells. Both shGFP (control; C,E) and shNKX6.1 (D,F) cells were analyzed. Nuclei were visualized by Hoechst 33342 (C'-F'). (G) Immunoblotting was performed to analyze protein levels of pSTAT3, STAT3, and NKX6.1. pSTAT3 signal was reduced following NKX6.1 knockdown without changes

in total STAT3 amount. Student's *t*-test was used to analyze significance. *: $P < 0.05$, **: $P < 0.01$. Error bars represent the standard deviations. Scale bars indicate 100 μm .

Fig. 4. NKX6.1 activates *IL6* promoter. (A,B) Relative luciferase activities to minimal promoter are shown. Values were obtained from the same data shown in Supplementary Fig. S5. (C) A pull-down assay with *IL6* promoter oligos was performed to analyze the binding potential of NKX6.1 to *IL6* promoter region. Protein lysate was obtained from SUM159 culture. (D) Competition assay with the proximal 100bp, 50bp, and 20bp fragments was performed. (E, F) ChIP assay of SUM159 cells having forced expression of FLAG or NKX6.1-FLAG protein was performed. Enrichment of *IL6* promoter region was analyzed by quantitative PCR (E) and regular PCR (F). (G) DNA sequence of the region between 50 bp and 20 bp is shown. Underlines indicate candidate sites for NKX6.1-regulated *IL6* expression. Bold letters indicate mutations. (H) Relative luciferase activity of cells having mutant construct is shown. Student's *t*-test was used to analyze significance. **: $P < 0.01$. Error bars represent the standard deviations.


Fig. 5. The NKX6.1 - IL-6 network regulates cell growth in basal-like breast cancer. (A,B) Immunoblotting on supernatant samples shows secreted IL-6-FLAG protein in SUM159 (A) and MDA-MB-231 cells (B). FLAG expression vector was used as a control. (C,D) Immunoblotting showed the restoration of the reduced pSTAT3 level of NKX6.1-depleted cells by IL-6-FLAG expression. (E,F) Cell growth assay was performed in the control and IL-6-FLAG expressing cells. Cell number was counted manually at day 4. In both SUM159 (E) and MDA-MB-231 cells (F), the reduced cell growth was recovered by IL6 forced expression. Student's *t*-test was used to analyze significance. *: $P < 0.05$, **: $P < 0.01$. Error bars represent the standard deviations.

Fig. 6. NKX6.1 is required for tumor formation. (A) Tumor formation rate is presented. SUM159 cells were injected into the fat-pad of 6-week-old female NOD/SCID mice. Four weeks after transplantation, tumor formation was assessed. Fisher's exact test was used to analyze significance. (B,C) Typical images of tumor formation. Tumors were observed at the point where IL-6-FLAG;shGFP cells were transplanted (B), but not where IL-6-FLAG;shNKX6.1 cells were transplanted (C).


Fig. 7. Negative feedback loop in the NKX6.1 - IL-6 network. (A) Relative mRNA levels of *NKX6.1* in IL-6 knockdown cells are graphed. (B) Relative mRNA levels of *NKX6.1* in STAT3 knockdown cells are graphed. The *NKX6.1* expression was increased by STAT3 knockdown in SUM159 and MDA-MB-231 cells. (C) Schematic diagram of the role of NKX6.1 in basal-like breast cancer. Student's *t*-test was used to analyze significance. *: $P < 0.05$, **: $P < 0.01$. Error bars represent the standard deviations.

Li Fig. 1


A




B




C





D











E







F




Li Fig. 2

Li Fig. 3




Li Fig. 4




Li Fig. 5


A




C




E




B



D



F



Li Fig. 6

A

Cell type	No. tumor formed / No. injected	
FLAG; shGFP	6 / 6	] $P = 0.0152$
FLAG; shNKX6.1	1 / 6	
IL-6-FLAG; shGFP	6 / 6	] $P = 0.0022$
IL-6-FLAG; shNKX6.1	0 / 6	


B

IL-6-FLAG; shGFP




C

IL-6-FLAG; shNKX6.1




Li Fig. 7


A



B



C



A homeobox protein, NKX6-1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells

Wenzhao Li, Junji Itou*, Sunao Tanaka, Tomomi Nishimura, Fumiaki Sato, Masakazu Toi

Supplementary material

- Supplementary figure S1
- Supplementary figure S2
- Supplementary figure S3
- Supplementary figure S4
- Supplementary figure S5
- Supplementary figure S6
- Supplementary figure S7
- Supplementary figure S8
- Supplementary table S1
- Supplementary table S2
- Supplementary table S3
- Supplementary table S4




Fig. S1. The *NKX6.1* expression was up-regulated in the patient with basal-like breast cancer. Data was obtained from GSE3744, and analyzed on Gene Expression Omnibus platform. Mann-Whitney *U*-test was used to analyze significance. *: $P < 0.05$. Error bars represent the ranges between maximum and minimum values.




Fig. S2. Truncated NKX6.1 is distributed to cytoplasm. (A-D) Immunostaining with anti-FLAG M2 antibody were performed in SUM159 (A, B) and MDA-MB-231 cells (C, D) having NKX6.1-FLAG or Truncated NKX6.1-FLAG expression. Nuclei were visualized by Hoechst 33342 (A'-D'). Bars indicate 100 μ m.




Fig. S3. Cell survival was reduced by shNKX6.1 expression, but not by NKX6.1 knockout. (A,B) Ratios of TUNEL-positive cells were analyzed in cells with shRNA-mediated NKX6.1 knockdown (A) and with CRISPR/Cas9-mediated NKX6.1 knockout (B). **: $P < 0.01$. Error bars represent the standard deviations.




Fig. S4. The expression of mesenchymal markers is not regulated by NKX6.1 in basal-like breast cancer. (A,B) Quantification of the mRNA levels for a mesenchymal marker *VIM* is shown. SUM159 (A) and MDA-MB-231 cells (B) were used. (C,D) Quantification of the mRNA levels for a mesenchymal marker *CDH2* is shown. SUM159 (C) and MDA-MB-231 cells (D) were used. No significant difference was observed between the control and NKX6.1-depleted cells. Student's *t*-test was used to analyze significance. Error bars represent the standard deviations.




Fig. S5. *NKX6.1* activates *IL6* promoter. (A) Construct of *IL6* promoter reporter. (B,C) Graphs of the raw data of reporter assay are shown. SUM159 (B) and MDA-MB-231 cells (C) were used. (D) Graph of the raw data of mutant construct with or without *NKX6.1* knockdown. Error bars represent the standard deviations. (E) EMSA shows a shifted band (arrow). The band was not seen when DNA oligo has a mutation shown in Fig. 4G Mut1. (F) Pull-down assay shows sequence specific binding of *NKX6.1*.




Fig. S6. The NKX6.1 - IL-6 network promotes cell proliferation. (A,B) Ratios of PCNA-positive cells were analyzed in IL-6 forced expression cell lines. Restoration of proliferation ability was observed. *: $P < 0.05$, **: $P < 0.01$. Error bars represent the standard deviations.




Fig. S7. NKX6.1 knockdown does not regulate the *IL6* expression in a colon cancer cell line, LoVo. (A) qRT-PCR assay showed the efficiency of NKX6.1 knockdown in LoVo cells. (B) Quantification of *IL6* mRNA level following *NKX6.1* knockdown in LoVo cells. The result shows no significant difference from the control group. Student's *t*-test was used to analyze significance. **: $P < 0.01$. Error bars represent the standard deviation.




Fig. S8. Relation between *NKX6.1* mRNA level and prognosis in the patients with invasive breast cancer. (A,B) Survival curves were depicted based on the data from two cohort studies which are publicly available. Data were analyzed by SurvExpress platform. Red and green lines indicate the *NKX6.1* high- and low expression groups, respectively.

Table S1. Sequences of qRT-PCR primers.

Gene	Primer	Sequence (5'→ 3')
<i>EF1A1</i>	EF1A1 F	AAATGACCCACCAATGGAAGCAGC
	EF1A1 R	TGAGCCGTGTGGCAATCCAATACA
<i>NKX1.1</i>	NKX1.1 F	ACGACACCAACGGCTACAG
	NKX1.1 R	CGCTTCGTCCTCGTCGTC
<i>NKX1.2</i>	NKX1.2 F	GGAAAGATGCCAGCTCCAG
	NKX1.2 R	CGCATCCTCCTCCTCTTCCG
<i>NKX2.1</i>	NKX2.1 F	CAACCTGGGCAACATGAGC
	NKX2.1 R	CCCATGAAGCGGGAGATG
<i>NKX2.2</i>	NKX2.2 F	CCTTCTACGACAGCAGCGA
	NKX2.2 R	CTTGGAGCTTGAGTCCTGAG
<i>NKX2.3</i>	NKX2.3 F	CTATGTCCACACGGTCCTG
	NKX2.3 R	AGTCTCCGGCCGTCTCTA
<i>NKX2.4</i>	NKX2.4 F	GGCAACATGGGCGAGCTG
	NKX2.4 R	TGAACCTGGAGATTGACGAGTAG
<i>NKX2.5</i>	NKX2.5 F	TTCTATCCACGTGCCTACAG
	NKX2.5 R	GTTGTCCGCCTCTGTCTTC
<i>NKX2.6</i>	NKX2.6 F	GAGGGTCAGAGGTTCACAA
	NKX2.6 R	CATCTCCAAGACTGCCTCAC
<i>NKX2.8</i>	NKX2.8 F	CTAGATTTACCCGAGCAGGAC
	NKX2.8 R	GGTCTCCAGGCTGCTCTC
<i>NKX3.1</i>	NKX3.1 F	GCAGAGACCGAGCCAGAAA
	NKX3.1 R	GCTTCTGCGGCTGCTTAG
<i>NKX3.2</i>	NKX3.2 F	GCCGCTTCCAAAGACCTAGA
	NKX3.2 R	GCCAACACCGTCGTCCTC
<i>NKX6.1</i>	NKX6.1 F	GGGCTCGTTTGGCCTATTC
	NKX6.1 R	CGTGCTTCTTCCTCCACTTG
<i>NKX6.2</i>	NKX6.2 F	CGAGAGCCAGGTGAAGGT
	NKX6.2 R	CCGAGTCCTGCTTCTTCTTG
<i>NKX6.3</i>	NKX6.3 F	GGAAGAAGCAGACACTCCTG
	NKX6.3 R	GCTCTTCTTCCGCCACTTG
<i>CDH1</i>	CDH1 F	TTGCAAATTCCTGCCATTCT
	CDH1 R	TCCTCCGAAGAAACAGCAAG
<i>VIM</i>	VIM F	TCTGGATTCACTCCCTCTGG
	VIM R	TCAAGGTCATCGTGATGCTG
<i>CDH2</i>	CDH2 F	GACAATGCCCCTCAAGTGTT
	CDH2 R	CCATTAAGCCGAGTGATGGT
<i>IL6</i>	IL6 F	GACAGCCACTCACCTCTTC
	IL6 R	TGCTTTCACACATGTTACTCTTG
<i>IL6 promoter</i>	IL6-pro F	AAAGGACGTCACATTGCAC
	IL6-pro R	ACTCTAATATTGAGACTCATGGGAA

Table S2. Sequences of shRNAs.

Target	Sequence (5'→ 3')
<i>GFP</i>	GCACGACTTCTTCAAGTCCGCCTCGAGGCGGACTTGAAGAAGTCGTGC
<i>NKX6.1</i>	GAAGACTTTTCGAACAAACAACTCGAGTTTGTGTTGTTTCGAAAGTCTTC
<i>IL6</i>	CTGGATTCAATGAGGAGACTTCTCGAGAAGTCTCCTCATTGAATCCAG
<i>STAT3</i>	GCACAATCTACGAAGAATCAACTCGAGTTGATTCTTCGTAGATTGTGC

Table S3. Sequences of oligos for EMSA

Oligo	Sequence (5'→ 3')
EMSA wild type	CTCCAACAAAGATTTATCAAATGTG
EMSA mutated	CTCCAACAAAGACCCCTCAAATGTG

Table S4. Cell proliferation genes changed by shNKX6.1 in SUM159 cells

Gene symbol	Log fold-change compared to control	Cell proliferation ¹	Positive for cell proliferation ²	Negative for cell proliferation ³
Reduced by shNKX6.1				
CSF3	-5.168		+	
CXCL8	-2.794			+
IL1B	-2.446		+	+
IL6	-2.291	+	+	+
EREG	-2.183	+	+	+
CDCA7L	-2.121		+	
SOD2	-2.056			+
RBPJ	-2.014		+	+
DHRS2	-1.996			+
IL7R	-1.967	+		
XDH	-1.759			+
HMGA1	-1.759			+
LIF	-1.672		+	+
MTBP	-1.605			+
KRT6A	-1.604		+	
IL1A	-1.489	+		+
NKX6-1	-1.482	+		
EPGN	-1.421		+	
TGFA	-1.419	+	+	
ICOSLG	-1.393		+	
BLM	-1.375		+	
EGR1	-1.307	+	+	
CDK2	-1.305		+	
PRDX1	-1.245	+		
ETV4	-1.235			+
BUB1	-1.224	+		
KIF15	-1.223	+		
CENPF	-1.217	+		
AKR1C2	-1.213		+	
TTK	-1.212		+	
XRCC4	-1.207		+	
CCNB1	-1.181		+	
MYH10	-1.178	+		
CNOT11	-1.171	+		
FERMT1	-1.171	+		
NAMPT	-1.140		+	
UTP20	-1.134			+
CXCL1	-1.131	+		+

FER	-1.131	+	+	
TFAP4	-1.121			+
ASPM	-1.113	+	+	
BIRC5	-1.111		+	
BNC1	-1.095		+	
BCAT1	-1.089	+		
RBP4	-1.076			+
CDC7	-1.070		+	
BUB1B	-1.063	+		
SLIT2	-1.063			+
IGFBP4	-1.058	+		
EFNB1	-1.058		+	
PA2G4	-1.056	+		
RAF1	-1.048	+		+
HELLS	-1.042		+	
DLGAP5	-1.042		+	
UHRF1	-1.033		+	
F3	-1.032	+		
NASP	-1.028		+	
MKI67	-1.027		+	
CDC6	-1.019			+
SOX7	-1.006			+

Increased by shNKX6.1

CRLF1	4.011		+	
GAL	3.308			+
IFIT3	2.902			+
SPRY1	2.837			+
PTN	2.667		+	
APOE	2.590			+
WNT5A	2.496	+	+	+
VIPR1	2.390		+	
ADRA1B	2.328	+		
IGFBP2	2.314		+	
MMP14	2.268	+		
ITGA1	2.190			+
NOTCH3	2.166		+	
CSPG4	2.069	+		
GAS1	1.933		+	+
KAT2B	1.930			+
CRIP2	1.919		+	
HCLS1	1.896		+	
EBI3	1.892		+	

IGFBP3	1.847	+		+
LEPREL2	1.845			+
MXD4	1.750			+
KDR	1.722		+	
ING4	1.665			+
CCL5	1.650		+	
SPEG	1.624			+
PDGFRB	1.615	+	+	
CTGF	1.596	+	+	
LIPA	1.591	+		
GATA3	1.548			+
TIMP2	1.542			+
EDN2	1.535		+	
CDKN2D	1.534			+
GRN	1.514		+	
TRPM4	1.479		+	
CD40	1.468	+	+	
ROS1	1.455	+		
MAGED1	1.447			+
TNFSF12	1.442		+	
CDKN1C	1.441			+
GNG2	1.426	+		
COL18A1	1.383		+	+
NMB	1.381		+	
DDR1	1.372			+
ECM1	1.367		+	
TGFBI	1.352	+		
SMAD6	1.329			+
CYP27B1	1.298			+
BTG1	1.288			+
PPAP2A	1.254			+
INSIG1	1.251		+	
ID2	1.244	+	+	+
RHBDF1	1.235	+		
TP53INP1	1.231			+
PTPRK	1.224			+
NUPR1	1.201			+
CLEC11A	1.199		+	
CDK5	1.179	+		
POLD4	1.158		+	
LOXL2	1.157	+		
ITGAV	1.139		+	
CDKN1B	1.137		+	+

CYR61	1.131	+	+	
FZD6	1.128	+		
EMX2	1.096	+		
ANG	1.065		+	+
IFITM1	1.061	+		
NRG1	1.057	+	+	
IGFBP7	1.054			+
DYNAP	1.049		+	
NCSTN	1.047	+		
GAS6	1.039	+	+	
AXIN2	1.034	+		+
PKD2	1.024			+
ITGB1	1.016		+	+
CTNNBIP1	1.014			+

¹Gene ontology number is GO:0008283 Cell proliferation

²Gene ontology number is GO:0008284 Positive for cell proliferation

³Gene ontology number is GO:0008285 Negative for cell proliferation